Source: Annual Congress 2008 - Asthma: growing understanding of influential factors
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Economidou, P. Lambrou, K. Samitas, E. Zervas, P. Karydi, A. Liapikou, S. Vittorakis, M. Gaga (Athens, Greece). Safety of research bronchoscopy in mild, moderate and severe asthma. Eur Respir J 2008; 32: Suppl. 52, 1146

Member's Comments

No comment yet.

Related content which might interest you: The management of mild asthma Source: Eur Respir J, 57 (4) 2003051; 10.1183/13993003.03051-2020 Year: 2021 Management of difficult-to-treat severe asthma Source: Eur Respir Mon 2011; 51: 282-296 Year: 2011 Evolution from mild to severe asthma; the severe asthma clinic perspective Source: International Congress 2019 – Clinical implications of asthma management Year: 2019 Safety of sputum monitoring in a severe asthma population - The Manchester severe asthma team experience Source: International Congress 2016 – Assessing lower airway inflammation with different tools Year: 2016 Special problems of severe asthma in childhood Source: Eur Respir Mon 2011; 51: 59-81 Year: 2011 Allergy in mild and severe asthma Source: Eur Respir J 2001; 18: Suppl. 33, 434s Year: 2001 The ERS/EAACI statement on severe exacerbations of asthma, and how to deal with non-allergic severe asthma Source: International Congress 2019 – Pathophysiology and clinical insights into severe non-allergic asthma Year: 2019 Impact of emphysema on the clinical presentation of mild to moderate COPD Source: Annual Congress 2010 - Lung imaging Year: 2010 Safety and feasibility of targeted lung denervation in patients with moderate to severe COPD Source: International Congress 2014 – Bronchoscopic treatment of emphysema: valves, coils and other Year: 2014 Predictors of severe exacerbations in patients with moderate and severe asthma Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018 Safety of bronchial thermoplasty out to 5 years in patients with severe refractory asthma: Research in severe asthma (RISA) trial Source: Annual Congress 2011 - New treatments for airway disease Year: 2011 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Refining asthma treatment for mild asthma Source: Virtual Congress 2020 – Rethinking asthma Year: 2020 Markers of eosinophilic airway inflammation in patients with severe and mild to moderate asthma Source: International Congress 2016 – Airway biomarkers Year: 2016 Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 One year following a real life experience of omalizumab for moderate to severe persistent allergic asthma in Malta Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Impact of moderate and severe exacerbations in severe COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Patients with asthma moderate and severe presents reduced moderate levels of physical activity, less aerobic conditioning and poorly control of the asthma Source: International Congress 2015 – Best abstracts in physical activity in chronic lung diseases Year: 2015